SCHEMBL793288

SCHEMBL793288

Cc1nn(C(=O)O)c2cc(Br)ccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRA P16234 1/20 0.54
CDK5 Q00535 1/20 0.54
TYRO3 Q06418 1/20 0.54
ELANE P08246 4/20 0.41
PLAU P00749 1/20 0.41
KMO O15229 1/20 0.40
MCL1 Q07820 1/20 0.40
ALDH1A1 P00352 2/20 0.39
HTT P42858 1/20 0.39
MAPK8 P45983 1/20 0.38
SLC22A12 Q96S37 3/20 0.37
RXFP1 Q9HBX9 2/20 0.37
PRNP P04156 1/20 0.37
PPARG P37231 1/20 0.37
NR2E3 Q9Y5X4 1/20 0.37
NCOR2 Q9Y618 1/20 0.37
EGLN1 Q9GZT9 1/20 0.36
MYC P01106 1/20 0.36
NR4A1 P22736 1/20 0.36
CASP3 P42574 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10112235 0.87 PDGFRA (0.70) PDGFRACDK5TYRO3ELANEPLAU
SCHEMBL4293410 0.87 ELANE (0.48) PDGFRACDK5TYRO3ELANEPLAU
SCHEMBL176951 0.82 ELANE (0.42) ELANEKMOHTTSLC22A12MYC
SCHEMBL1944896 0.81 PDGFRA (0.75) PDGFRACDK5TYRO3ELANEKMO
SCHEMBL28311685 0.81 SLC22A12 (0.56) ELANEKMOHTTSLC22A12MEN1
SCHEMBL3699843 0.81 ELANE (0.41) PDGFRACDK5TYRO3ELANEKMO
SCHEMBL17514107 0.81 ELANE (0.41) ELANEKMOALDH1A1SLC22A12
SCHEMBL20740648 0.80 PDGFRA (0.50) PDGFRACDK5TYRO3ELANEKMO
SCHEMBL11232 0.80 PDGFRA (0.47) PDGFRACDK5TYRO3ELANEPLAU
SCHEMBL788386 0.78 PDGFRA (0.48) PDGFRACDK5TYRO3ELANEKMO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3444242-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2019-02-20 EP disclosed
EP-2616443-A1 PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS Exelixis, Inc. (US) 2013-07-24 EP disclosed
US-20130165440-A1 JAK1 Inhibitors EXELIXIS, INC. (US) 2013-06-27 US disclosed
WO-2012037132-A1 PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS EXELIXIS, INC. (US) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165440-A1 JAK1 Inhibitors JAK1, JAK2, JAK3 PDGFRA 203/4885CDK5 1089/4885TYRO3 299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.